MX2014010989A - Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiatricos. - Google Patents
Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiatricos.Info
- Publication number
- MX2014010989A MX2014010989A MX2014010989A MX2014010989A MX2014010989A MX 2014010989 A MX2014010989 A MX 2014010989A MX 2014010989 A MX2014010989 A MX 2014010989A MX 2014010989 A MX2014010989 A MX 2014010989A MX 2014010989 A MX2014010989 A MX 2014010989A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutically acceptable
- ester
- acceptable salt
- treatment
- psychiatric disorders
- Prior art date
Links
- 208000020016 psychiatric disease Diseases 0.000 title abstract 2
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical class COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 title 1
- 150000002148 esters Chemical class 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 6
- 239000003693 atypical antipsychotic agent Substances 0.000 abstract 1
- 229940127236 atypical antipsychotics Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere un método de tratamiento de un paciente que sufre de un trastorno psiquiátrico que comprende administrar internamente al paciente una cantidad eficaz de R-P88, o una sal farmacéuticamente aceptable de la misma, o un éster de R-P88 o una sal farmacéuticamente aceptable de tal éster , una o dos veces por día, así como a una composición farmacéutica que comprende R-P88 o una sal farmacéuticamente aceptable de la misma, o un éster de R-P88 o una sal farmacéuticamente aceptable de un éster de R-P88, y un vehículo farmacéuticamente aceptable. Y al uso del R-P88 o una sal farmacéuticamente aceptable del mismo, o un éster de R-P88 o una sal farmacéuticamente aceptable de un éster de R-P88 para su uso en la fabricación de un medicamento útil para el tratamiento de un trastorno susceptible de tratamiento con un antipsicótico atípico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610664P | 2012-03-14 | 2012-03-14 | |
| PCT/US2013/031413 WO2013138602A1 (en) | 2012-03-14 | 2013-03-14 | An iloperidone metabolite for use in the treatment of psychiatric disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014010989A true MX2014010989A (es) | 2015-03-10 |
| MX374067B MX374067B (es) | 2020-07-30 |
Family
ID=48407766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014010989A MX374067B (es) | 2012-03-14 | 2013-03-14 | Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiatricos. |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10874659B2 (es) |
| EP (2) | EP2825167B1 (es) |
| JP (5) | JP2015510893A (es) |
| KR (2) | KR20170008327A (es) |
| CN (2) | CN104203240A (es) |
| AU (2) | AU2013232014B2 (es) |
| BR (1) | BR112014022687A8 (es) |
| CA (1) | CA2865845C (es) |
| CL (1) | CL2014002430A1 (es) |
| CO (1) | CO7091183A2 (es) |
| ES (2) | ES2773711T3 (es) |
| IL (1) | IL234412B (es) |
| IN (1) | IN2014DN08495A (es) |
| MX (1) | MX374067B (es) |
| RU (1) | RU2651710C2 (es) |
| WO (1) | WO2013138602A1 (es) |
| ZA (1) | ZA201406369B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107249586A (zh) | 2015-02-17 | 2017-10-13 | 万达制药公司 | 用于治疗精神分裂症的伊潘立酮 |
| US11214827B2 (en) | 2018-08-30 | 2022-01-04 | Vanda Pharmaceuticals Inc. | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone |
| AU2023408198A1 (en) * | 2022-12-19 | 2025-05-29 | Vanda Pharmaceuticals Inc. | Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia |
| CN121218989A (zh) * | 2023-06-02 | 2025-12-26 | 万达制药公司 | 使用伊潘立酮的治疗方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364866A (en) | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| US7029694B2 (en) | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| ES2370634T3 (es) * | 2001-08-31 | 2011-12-21 | Novartis Ag | Isómeros ópticos de un metabolito de iloperidona. |
| PT1458888E (pt) | 2001-12-10 | 2011-06-01 | Novartis Ag | Métodos para tratar a psicose e a esquizofrenia baseados em polimorfismos no gene do cntf |
| TW200410955A (en) | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
| GB0322994D0 (en) * | 2003-10-01 | 2003-11-05 | Novartis Ag | Organic compounds |
| EP1799865B1 (en) | 2004-09-30 | 2012-06-06 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| US20100063093A1 (en) * | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| JP2009538331A (ja) * | 2006-05-22 | 2009-11-05 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | 抑うつ障害のための治療 |
| ES2542967T3 (es) | 2007-03-29 | 2015-08-13 | Vanda Pharmaceuticals Inc. | Método de predecir una predisposición a la prolongación de QT |
| JP5653753B2 (ja) | 2007-09-10 | 2015-01-14 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Ｓｎｐ遺伝子型に基づくｑｔ延長の予測 |
| WO2009036056A1 (en) | 2007-09-10 | 2009-03-19 | Vanda Pharmaceuticals, Inc. | Antipsychotic treatment based on snp genotype |
| US9074255B2 (en) | 2009-04-06 | 2015-07-07 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to QT prolongation |
| SI3023506T1 (en) | 2009-04-06 | 2018-08-31 | Vanda Pharmaceuticals Inc. | A method of treatment based on polymorphisms of the KCNQ1 gene |
| US9072742B2 (en) | 2009-04-06 | 2015-07-07 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to QT prolongation |
| JP5881598B2 (ja) | 2009-04-06 | 2016-03-09 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Ａｂｃｃ２遺伝子の配列又はその産物に基づいてｑｔ延長に対する素因を予測する方法 |
| WO2010132866A1 (en) | 2009-05-15 | 2010-11-18 | Vanda Pharmaceuticals Inc. | Antipsychotic treatment based on drd2 or ankk1 snp genotype |
-
2013
- 2013-03-14 CN CN201380013841.XA patent/CN104203240A/zh active Pending
- 2013-03-14 EP EP13721817.8A patent/EP2825167B1/en active Active
- 2013-03-14 CA CA2865845A patent/CA2865845C/en active Active
- 2013-03-14 AU AU2013232014A patent/AU2013232014B2/en active Active
- 2013-03-14 MX MX2014010989A patent/MX374067B/es active IP Right Grant
- 2013-03-14 KR KR1020177001093A patent/KR20170008327A/ko not_active Ceased
- 2013-03-14 BR BR112014022687A patent/BR112014022687A8/pt not_active Application Discontinuation
- 2013-03-14 EP EP18152636.9A patent/EP3345603B1/en active Active
- 2013-03-14 RU RU2014141112A patent/RU2651710C2/ru active
- 2013-03-14 KR KR1020147026434A patent/KR20140121487A/ko not_active Ceased
- 2013-03-14 JP JP2015500615A patent/JP2015510893A/ja active Pending
- 2013-03-14 ES ES18152636T patent/ES2773711T3/es active Active
- 2013-03-14 CN CN201810683727.2A patent/CN108938632A/zh active Pending
- 2013-03-14 WO PCT/US2013/031413 patent/WO2013138602A1/en not_active Ceased
- 2013-03-14 US US14/384,401 patent/US10874659B2/en active Active
- 2013-03-14 IN IN8495DEN2014 patent/IN2014DN08495A/en unknown
- 2013-03-14 ES ES13721817.8T patent/ES2677474T3/es active Active
-
2014
- 2014-08-29 ZA ZA2014/06369A patent/ZA201406369B/en unknown
- 2014-09-01 IL IL234412A patent/IL234412B/en active IP Right Grant
- 2014-09-12 CL CL2014002430A patent/CL2014002430A1/es unknown
- 2014-10-09 CO CO14224666A patent/CO7091183A2/es unknown
-
2016
- 2016-05-30 AU AU2016203591A patent/AU2016203591B2/en active Active
- 2016-11-07 JP JP2016217680A patent/JP2017061506A/ja active Pending
-
2018
- 2018-09-10 JP JP2018169090A patent/JP7151029B2/ja active Active
-
2020
- 2020-09-28 JP JP2020162569A patent/JP2021001221A/ja active Pending
- 2020-09-30 US US17/039,769 patent/US20210015809A1/en not_active Abandoned
-
2022
- 2022-12-01 JP JP2022192922A patent/JP2023022243A/ja active Pending
-
2023
- 2023-09-26 US US18/373,205 patent/US20240016791A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501997A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| CR20140108A (es) | Compuesto de ciclopropanoamina | |
| MX2016004580A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| UA109991C2 (xx) | Карбаматні сполуки, їх отримання і застосування | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| DOP2013000192A (es) | Compuestos y composiciones como inhibidores de la trk | |
| NZ702663A (en) | Nuclear transport modulators and uses thereof | |
| MX2015016983A (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| MX350666B (es) | Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia. | |
| EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| UA116999C2 (uk) | Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| MX377089B (es) | Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral. | |
| WO2012170918A3 (en) | Methods of treatment for retinal diseases | |
| EP2874626A4 (en) | TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS | |
| PE20151526A1 (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod | |
| MX376496B (es) | Agente protector para queratoconjuntiva o agente supresor para el trastorno queratoconjuntival. | |
| EP2874622A4 (en) | TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS | |
| UY34896A (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina | |
| MX2014010989A (es) | Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiatricos. | |
| PE20151424A1 (es) | Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales | |
| BR112016016098A2 (pt) | Compostos orgânicos | |
| AR092104A1 (es) | LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |